ANN ARBOR, Mich. (February 18, 2009) – NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing with Perseus LLC and other existing investors. To date, over $80 million in funding has been directed toward the development of the company’s NanoStatTM technology platform.
The series B funding will be used by the company to complete a phase 1 study investigating
Continue reading: NanoBio Corporation Raises $12 Million in Series B Financing
ANN ARBOR, Mich. (Jan. 29, 2009) – Scientists at NanoBio Corp. and the University of Michigan have demonstrated in the laboratory that their novel topical nanoemulsion kills the highly resistant strains of bacteria that cause chronic illness and death among individuals with cystic fibrosis.
The findings are significant because they represent a new model for treating resistant bacteria that lead to pulmonary failure in patients with cystic fibrosis, according to the study authors. Results of the
Continue reading: Nanoemulsion Kills Highly Resistant Bacteria Found in Patients with Cystic Fibrosis
ANN ARBOR, Mich. (7/8/2008)-NanoBio® Corp., a biopharmaceutical company focused on developing and commercializing novel products to prevent and treat infectious diseases, today announced the appointment of Dr. Daniel B. Dubin to its board of directors.
Dr. Dubin currently serves as Vice Chairman and a Director at Leerink Swann, a leading healthcare and biotechnology investment banking firm.
“Dan’s keen understanding of the life sciences investment banking field and his clinical experience as a dermatologist bring a dual perspective
Continue reading: Daniel B. Dubin, MD Joins NanoBio Corp.’s Board of Directors
ANN ARBOR, Mich., June 24, 2008-NanoBio Corp. announced today that it has been named to the annual FierceBiotech “Fierce 15″ list, designating NanoBio as one of the top biotechnology companies of 2008.
The editors of FierceBiotech evaluated hundreds of privately held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships and competitive market position. NanoBio was determined to be one of the “fiercest,” proven by its creativity and innovations in the
Continue reading: NanoBio Named One of Top 15 Biotech Companies
Loading ...